Loading
A phase 3 trial of Efbemalenograstim alfa and Pegfilgrastim in Breast cancer, run by EVIVE Biotechnology, completed.
Neulasta-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy is a phase 3 interventional study registered as NCT03252431 by EVIVE Biotechnology, with 393 participants recorded, started 2018-04-12 and reaching its primary completion in 2019-09-25. Interventions recorded: F-627, Neulasta. Conditions recorded: Breast Cancer, Neutropenia.
Linked to the drug Efbemalenograstim alfa because the registry names it among its interventions and Breast cancer among its conditions. Registry record only: no result has been read by an editor.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
393 enrolled.
SD 0.51; Figures from the ClinicalTrials.gov results section (first posted 2021-05-07), not from a publication · SD 0.45
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Duration in Days of Grade 4 Neutropenia in Chemotherapy Cycle 1primary | F-627 | 197 | 0.2 days | - | - | link |
| Neulasta | 196 | 0.2 days |
Shares Evive Biotech, Efbemalenograstim alfa, Male breast cancer, Breast cancer (all types) and the tag pipeline.
Shares Evive Biotech, Efbemalenograstim alfa, Breast cancer (all types) and the tag pipeline.
Shares Pegfilgrastim, Male breast cancer, Breast cancer (all types) and the tag pipeline.
Shares Male breast cancer, Breast cancer (all types) and the tag pipeline.
Shares Pegfilgrastim, Breast cancer (all types) and the tag pipeline.
Shares Pegfilgrastim, Breast cancer (all types) and the tag pipeline.
Shares Pegfilgrastim, Breast cancer (all types) and the tag pipeline.
Shares Pegfilgrastim and the tag pipeline.